Medicare And Lecanemab: House Republicans Lack ‘Proactive’ Plan For Ensuring Coverage

With a slim House majority, will Republicans wade into Medicare coverage policy for a promising Alzheimer’s drug and the new Medicare price negotiation program? Democratic Senate could offer ‘counter oversight’ hearings.

Looking Ahead To The Next Two Years In Congress • Source: Shutterstock

Congressional Republicans may need to “scramble” to help ensure meaningful Medicare coverage for Eisai Co., Ltd./Biogen, Inc.’s lecanemab if it is approved by the US Food and Drug Administration for Alzheimer's disease next year, according to health policy expert Jennifer Young.

Young who is a partner at the health care policy consultancy Tarplin, Downs and Young, discussed House Republican’s health care priorities in the coming session as they take control of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Elections

Korean Pharma Industry Proposes Policies As Election Nears

 
• By 

As South Korea gears up for a snap presidential election, its biopharma industry proposes key desired policies to candidates, most of whom have not laid out detailed plans of their own for the sector.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By 

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

‘A Lot Of That, It’s Meant To Start A Conversation’: How To Work With Trump

 

Biotech execs and lobbyists try to explain the Trump Administration's policy strategy and how to thrive in it.

Bracing For RFK At HHS: Vaccine Safety Commission Likely First Step

 

Robert F. Kennedy Jr. will become HHS secretary while retaining his anti-vaccine positions. His first action likely will be creating a new safety commission, which industry must hope holds off more drastic action.

More from Legislation

Korean Pharma Industry Proposes Policies As Election Nears

 
• By 

As South Korea gears up for a snap presidential election, its biopharma industry proposes key desired policies to candidates, most of whom have not laid out detailed plans of their own for the sector.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.